Lipid 88 |Lipid88|ionizable cationic lipid for LNP

Cas No.:	2982842-99-7
Chemical Name:	Lipid 88
Synonyms:	tetrakis(2-((((2-butyloctyl)oxy)carbonyl)oxy)ethyl) 3,3',3'',3'''-(((methylazanediyl)bis(propane-3,1-diyl))bis(azanetriyl))tetrapropionate;Lipid-88， Lipid 88
SMILES:	CCCCCCC(CCCC)COC(OCCOC(CCN(CCC(OCCOC(OCC(CCCC)CCCCCC)=O)=O)CCCN(C)CCCN(CCC(OCCOC(OCC(CCCC)CCCCCC)=O)=O)CCC(OCCOC(OCC(CCCC)CCCCCC)=O)=O)=O)=O
Formula:	C₇₉H₁₄₇N₃O₂₀
M.Wt:	1459.0
Purity:	ELSD-HPLC>95%
Sotrage:	1 year -20°C
Publication:	Ye, Z., Bonam, S.R., McKay, L.G.A., et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proc. Natl. Acad. Sci. USA 120(52), e2311752120 (2023).

Description:

Lipid88 is a high-performance, novel ionizable lipid component engineered for advanced mRNA-LNP vaccine delivery. LNP88 formulation demonstrates superior biodistribution, achieving >10-fold higher transfection efficiency in spleen and lymph nodes compared to benchmark lipids like ALC-0315 via intramuscular delivery. When encapsulating antigen-encoding mRNA (e.g., optimized mCSA construct), Lipid-88 based LNPs drive robust humoral and cellular immunity, enabling complete protection against challenging SARS-CoV-2 variants (WA1/2020, Omicron BA.1, BQ.1) in preclinical models. Its design prioritizes potent immunogenicity with favorable safety profiles.

References:

Ye, Z., Bonam, S.R., McKay, L.G.A., et al. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants. Proc. Natl. Acad. Sci. USA 120(52), e2311752120 (2023).

Cat. No.	Product name	Field of application
DC60821	Lipid TOT-5	TOT-5, a tri-oleoyl-Tris ionizable lipid (pKa 6.2), enables splenic B cell-targeted mRNA delivery via 15% DSPC-incorporated LNPs. Its charge-neutral, hydrophobic surface minimizes hepatic ApoE uptake and enhances complement C3 adsorption, facilitating CD21/35-mediated uptake by marginal zone B cells. In vivo, intravenous 15%DSPC-LNPs showed 8-fold higher spleen-to-liver luciferase expression vs 3%DSPC, with anti-CD21/35 blocking 60% B cell uptake. Intramuscular administration induced robust OVA-specific IgG (10^5 titer) and CTL responses (3.5% tetramer+ CD8+ T cells) while reducing hepatotoxicity (ALT/AST levels ≤40 U/L vs SM-102-LNPs' 80-120 U/L). Cryo-ET confirmed stable lamellar structures (80-100 nm, ζ-potential -2 mV). This formulation achieves safe, ligand-free splenic targeting for mRNA vaccines.
DC66219	Lipid 88	Lipid88 is a high-performance, novel ionizable lipid component engineered for advanced mRNA-LNP vaccine delivery. LNP88 formulation demonstrates superior biodistribution, achieving >10-fold higher transfection efficiency in spleen and lymph nodes compared to benchmark lipids like ALC-0315 via intramuscular delivery. When encapsulating antigen-encoding mRNA (e.g., optimized mCSA construct), Lipid-88 based LNPs drive robust humoral and cellular immunity, enabling complete protection against challenging SARS-CoV-2 variants (WA1/2020, Omicron BA.1, BQ.1) in preclinical models. Its design prioritizes potent immunogenicity with favorable safety profiles.